Overview

A Study of Administration of RoActemra/Actemra (Tocilizumab) by Auto-injector Vs. Pre-filled Syringe in Healthy Volunteers

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This open-label, multi-center study will compare the bioavailability of RoActemra/Actemra (tocilizumab) administration by auto-injector versus pre-filled syringe in healthy volunteers. Healthy volunteers will receive a single dose of RoActemra/Actemra (tocilizumab). The anticipated time of study duration is 28 days.
Phase:
Phase 1
Details
Lead Sponsor:
Hoffmann-La Roche